T002 HHSN261201500036I-75N91018F00011 (Old 000509388-T011) Preclinical Efficacy and Intermediate Endpoint Biomarkers - Further Development of Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer

Grant

Date/time Interval

  • April 1, 2020 - March 16, 2022

    • Awarded By

    Total Award Amount

  • 515197.00

    • Direct Costs

  • 441927.00

    • Sponsor Award Id

  • HHSN261201500036I-75N91018F00011

    • Contributor

  • Gregory Kennedy M.D.   Principal Investigator